It is time to take profits on Acorda Therapeutics (ACOR). Consider taking profits on the entire position of Acorda Therapeutics right here at $23.08.
Ampyra, the drug that has caused most excitement in Acora Therapeutics, is not proving to be a very good drug as we had predicted. Please see prior post on Acorda Therapeutics. However, this is company is highly promotional and periodically tends to release meaningless press releases that run the stock up.
The plan is to short Acorda Therapeutics again on any run up. A signal will be provided in real-time on the Real Time Feed of the ZYX Short Sell Change Alert.
